Stenocare A/S
CSE:STENO
Net Margin
Stenocare A/S
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
DK |
S
|
Stenocare A/S
CSE:STENO
|
23.4m DKK |
-1 763%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
722.9B USD |
23%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
359B USD |
24%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
35%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
206.2B CHF |
14%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
185.9B CHF |
24%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
161.7B GBP |
14%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
200.1B USD |
27%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
136.3B USD |
13%
|
Stenocare A/S
Glance View
Stenocare A/S engages in the cultivation, manufacture, and distribution of medical cannabis products. The Company’s business model has two divisions: Import and wholesale of finished medical cannabis products for Danish patients, as well as Operate own cultivation- and production facility in Denmark to produce finished cannabis products for Danish and European patients. The firm distributes its products through pharmacies and hospitals. Stenocare's head office is located in Randers, Denmark.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Stenocare A/S's most recent financial statements, the company has Net Margin of -1 763%.